RYTM
Rhythm Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Rhythm Pharmaceuticals has 9 disclosed suppliers and 1 disclosed customer in SEC filings.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceUnder the terms of the Camurus license agreement, assuming that the weekly formulation of setmelanotide is successfully developed, receives regulatory approval and is commercialized, Camurus may receive aggregate payments of up to $64.8 million upon the achievement of certain development and commercial milestones under the license agreement and royalties on future product sales.
RYTM 10-Kaccession 0001628280-26-012399
SentenceOur partner CGC Genetics Unilabs conducts genetic testing for ROAD.
RYTM 10-Kaccession 0001628280-26-012399
SentenceOn June 16, 2022, we entered into the RIFA with HealthCare Royalty, for a total investment amount of up to $100 million.
RYTM 10-Kaccession 0001628280-26-012399
SentenceWe have licensed our rights to setmelanotide from Ipsen, and our rights to bivamelagon from LGC.
RYTM 10-Kaccession 0001628280-26-012399
SentenceUnder the terms of the LG Chem license agreement, we have paid LG Chem $80 million in cash and issued shares to them of our common stock with an aggregate value of $20 million.
RYTM 10-Kaccession 0001628280-26-012399
SentencePursuant to the terms of the license agreement, we obtained exclusive worldwide rights to develop LGC's proprietary compound bivamelagon.
RYTM 10-Kaccession 0001628280-26-012399
SentenceWe have entered into process development and manufacturing service agreements with our CMOs, PolyPeptide Group, Braine L'Alleud, or Polypeptide, Neuland Laboratories, and Astrea Monts S.A.S. (formerly Recipharm), or Astrea, for certain process development and manufacturing services for regulatory starting materials and/or raw materials in connection with the manufacture of setmelanotide.
RYTM 10-Kaccession 0001628280-26-012399
SentenceOur U.S. partner, Prevention Genetics, a subsidiary of Exact Sciences Corp., a Clinical Laboratory Improvement Amendments-College of American Pathologists of CLIA/CAP-certified independent laboratory, conducts the genetic testing for URO.
RYTM 10-Kaccession 0001628280-26-012399
SentenceIn addition, as part of the program, licensed genetic counselors from PWN Health, a leading provider of professional guidance for diagnostic and genetic testing, are available to advise participating individuals.
RYTM 10-Kaccession 0001628280-26-012399
SentenceDuring the year ended December 31, 2025 , we recognized a reduction of previously recognized license revenue of $5.0 million in connection with the termination of our exclusive license agreement with RareStone.
RYTM 10-Kaccession 0001628280-26-012399
Rhythm Pharmaceuticals, Inc.
91.74
+2.92%
vs ±11.3% implied · ×0.26
shaded = implied · ▲▼ = realized
Largest filed tie
—
Expected move
No implied move.